Journal of Gastroenterology and Hepatology｜Compared with chemotherapy alone as the first-line treatment, PD-1 inhibitor combined with chemotherapy can significantly improve the median progression-free survival time of patients with metastatic or recurrent cholangiocarcinoma[J]. J Clin Hepatol, 2022, 38(2): 401-401. DOI: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj5.
Journal of Gastroenterology and Hepatology｜Compared with chemotherapy alone as the first-line treatment, PD-1 inhibitor combined with chemotherapy can significantly improve the median progression-free survival time of patients with metastatic or recurrent cholangiocarcinoma[J]. J Clin Hepatol, 2022, 38(2): 401-401. DOI: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj5.
DownLoad: